PSMA7, A potential biomarker of diseases

Protein and Peptide Letters

Volumn 16, Issue 5, 2009, Pages 486-489

  Du, Hongyan ^a   Huang, Xiang ^a   Wang, Suihai ^a   Wu, Yingsong ^a   Xu, Weiwen ^a   Li, Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Disease tumor; Proteasome; PSMA7; Ubiquitin proteasome pathway

Indexed keywords

BIOLOGICAL MARKER; PROTEASOME;

ANIMAL; ARTICLE; CELL CYCLE; GENERAL ASPECTS OF DISEASE; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; VIRUS REPLICATION;

ANIMALS; BIOLOGICAL MARKERS; CELL CYCLE; DISEASE; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; VIRUS REPLICATION;

EID: 67649359724     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986609788167824     Document Type: Article

References (47)

1. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev.Biochem., 1998, 67, 425-479.
2. Varshavsky, A. Regulated protein degradation. Trends Biochem.Sci., 2005, 30(6), 283-286.
3. Deshaies, R.J. Make it or break it: the role of ubiquitin- dependentproteolysis in cellular regulation. Trends Cell Biol., 1995, 5(11),428-434.
4. Spataro, V.; Norbury, C.; Harris, A.L. The ubiquitin-proteasomepathway in cancer. Br. J. Cancer, 1998, 77(3), 448-455.
5. Burkhardt, D. Role of proteasomes in disease. BMC Biochemistry2007, S(Suppl 1), S3.
6. Wang, X.; Guerrero, C.; Kaiser, P.; Huang, L. Proteomics of pro-teasome complexes and ubiquitinated proteins. Expert. Rev. Pro-teomic, 2007, 4(5), 649-665.
7. Moran, E.; Nencioni, A. The role of proteasome in malignant diseases. J. Buon., 2007, 12 (Suppl 1), S95-99.
8. Iwafune, Y.; Kawasaki, H.; Hirano, H. Electrophoretic analysis of phosphorylation of the yeast 20S proteasome. Electrophoresis, 2002, 23(2), 329-338.
9. Coux, O.; Tanaka, K.; Goldberg, A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem., 1996, 65, 801-847.
10. Orlowski, M.; Wilk, S. Catalytic Activities of the 20 S Proteasome, a Multicatalytic Proteinase Complex. Arch. Biochem. Biophys., 2000, 383(1), 1-16.
11. Horiguchi, R.; Yoshikuni, M.; Tokumoto, M.; Nagahama, Y.; To- kumoto, T. Identification of a protein kinase which phosphorylates a subunit of the 26S proteasome and changes in its activity during meiotic cell cycle in goldfish oocytes. Cell Signal., 2005, 17(2),205-215.
12. Liu, X.; Huang, W.; Li, C.F.; Li, P.;Yuan, J.; Li, X.R.; Qiu, X.B.;Ma, Q.J.; Cao, C., Interaction between c-Abl and Arg tyrosine kinases and proteasome subunit PSMA7 regulates proteasome degradation. Mol. Cell, 2006, 22(3), 317-327.
13. Semenza, G.L. Regulation of mammalian O2 homeostasis by hy- poxia-inducible factor 1. Annu. Rev. Cell Dev. Biol., 1999, 15, 551-578.
14. Wang, G.L.; Jiang, B.H.; Rue, E.A.; Semenza, G.L. Hypoxia- inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA, 1995, 92(12), 5510-5514.
15. Pugh, C.W.; O'Rourke, J.F.; Nagao, M.; Gleadle, J.M.; Ratclie, P.J.Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J. Biol. Chem., 1997, 272(17),11205-11214.
16. Huang, L.E.; Arany, Z.; Livingston, D.M.; Bunn, H.F. Activation of hypoxia-inducible transcription factor depends primarily upon re- dox-sensitive stabilization of its alpha subunit. J. Biol. Chem., 1996, 271(50), 32253-32259.
17. Huang, L.E.; Gu, J.; Schau, M.; Bunn, H.F. Regulation of hypoxia- inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. A- cad. Sci. USA, 1998, 95(14), 7987-7992.
18. Jiang, B.H.; Zheng, J.Z.; Leung, S.W.; Roe, R.; Semenza, G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem., 1997, 272(31), 19253-19260.
19. Cho, S.; Choi, Y.J.; Kim, J.M.; Jeong, S.T.; Kim, J.H.; Kim, S.H.; Ryu, S.E. Binding and regulation of HIF-1alpha by a subunit of the proteasome complex, PSMA7. FEBSLett., 2001, 498(1), 62-66.
20. Haviv, I.; Vazl, D.; Shaul, Y. The X protein of hepatitis B virus coactivates potent activation domains. Mol. Cell. Biol., 1995, 15(2), 1079-1085.
21. Natoli, G.; Avantaggiati, M. L.; Chirillo, P.; Costanzo, A.; Artini, M.; Balsano, C.; Levrero, M. Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX. Mol. Cell. Biol., 1994, 14(2), 989-998.
22. Mukherjee, S.; Dong, J.B.; Heincelman, C.; Lenhart, M.; Welford, A.; Wandinger-N. A. Functional analyses and interaction of the XAPC7 proteasome subunit with Rab7, Meth. In Enzymology, 2005, 403, 650-663.
23. Dong, J.B.; Chen, W.; Welford, A.; Wandinger-Ness, A. The proteasome alpha-subunit XAPC7 interacts specifically with Rab7 and late endosomes. J. Biol. Chem., 2004, 279(20), 21334-21342.
24. Feng, Y.; Press, B.; Wandinger-Ness, A. Rab 7: an important regulator of late endocytic membrane traffic. J. Cell Biol., 1995, 131(6 Pt 1), 1435-1452.
25. Chen, H.S.; Kaneko, S.; Girones, R.; Anderson, R.W.; Hornbuckle, W.E.; Tennant, B.C.; Cote, P.J.; Gerin, J.L.; Purcell, R.H.; Miller,R.H. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J. Virol., 1993, 67(3), 1218-1226.
26. Zoulim, F.; Saputelli, J.; Seeger, C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol., 1994, 68(3),2026-2030.
27. Aufiero, B.; Schneider, R. J. The hepatitis B virus X-gene product trans-activates both RNA polymerase II and III promoters. EMBOJ., 1990, 9(2), 497-504.
28. Cross, J. C.; Wen, P.; Rutter, W. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc. Natl. Acad. Sci. USA, 1993,90, 8078-8082.
29. Colgrove, R.; Simon, G.; Ganem, D. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J. Virol., 1989, 63(9), 4019-4026.
30. Seto, E.; Mitchell, P. J.; Yen, T. S. B. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature (London), 1990, 44, 72-74.
31. Kim, C. M.; Koike, K.; Saito, I.; Miyamura, T.; Jay, G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature, 1991, 351(6324), 317-320.
32. Huang, J.K.; Kwong, J.; Sun, E.C.; Liang, T. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J. Virol.,1996, 70(8), 5582-5591.
33. Zhang, Z.S.; Torii, N.; Furusaka, A.; Malayaman, N.; Hu, Z.Y.;Liang, T. Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex. J.Biol. Chem., 2000, 275(20), 15157-15165.
34. Kruger, M.; Beger, C.; Wong-Staal, F. Use of ribozymes to inhibitgene expression. Methods Enzymol., 1999, 306, 207-225.
35. James, H. A.; Gibson, I. The therapeutic potential of ribozymes.Blood, 1998, 91(2), 371-382.
36. Muotri, A.R.; da Veiga Pereira, L.; dos Reis Vasques, L.; Menck, C.F. Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. Gene, 1999, 237(2), 303-310.
37. Kruger, M.; Beger, C.; Welch, P.J.; Barber, J.R.; Manns, M.P.; Wong-Staal, F. Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mole. Cell. Biol., 2001, 21(24), 8357-8364.
38. Kruger, M.; Beger, C.; Welch, P.J.; Barber, J.R.; Wong-Staal, F. CSPACE (cleavage-specific amplification of cDNA ends): a novel method of ribozyme-mediated gene identification. Nucleic Acids Res., 2001, 29(19), E94.
39. 39]Goldberg, A. L.; Rock, K. L. Proteolysis, proteasomes and antigenpresentation. Nature, 1992, 357(6377), 375-379.
40. Schwartz, O.; Marechal, V.; Friguet, B.; Arenzana-Seisdedos, F.; Heard, J.M. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J. Virol., 1998, 72(5), 3845-3850.
41. Jarrousse, A.S.; Gautier, K.; Apcher, S.; Badaoui, S.; Boissonnet,G.; Dadet, M.H.; Henry, L.; Bureau, J.P.; Schmid, H.P.; Petit, F.Relationships between proteasomes and viral gene products. Mol. Biol. Rep., 1999, 26(1-2), 113-117.
42. Israeli, O.; Goldring-Aviram, A.; Rienstein, S.; Ben-Baruch, G.; Korach, J.; Goldman, B.; Friedman, E. In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet., 2005, 160(1), 35-42.
43. El-Rifai, W.; Frierson, H.F. Jr. Moskaluk, C.A.; Harper, J.C.;Petroni, G.R.; Bissonette, E.A.; Jones, D.R.; Knuutila, S.; Powell, S.M. Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology, 2001,121(3), 592-598.
44. May, W. A.; Gishizky, M. L.; Lessnick, S. L. Ewing sarcoma 11;22translocation produces, Proc. Natl. Acad. Sci. USA, 1993, 90, 5752-5756.
45. Ohnami, S.; Matsumoto, N.; Nakano, M. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. Cancer Res., 1999, 59(21), 5565-5571.
46. Hu, X.T.; Chen, W.; Wang, D.; Shi, Q.L.; Zhang, F.B.; Liao, Y.Q.; Jin, M.; He, C. The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer. Oncol. Rep., 2008, 19(2), 441-446.
47. Shi, Y.-Y.; Wang, H.-C.; Yin, Y.-H.; Sun, W.-S.; Li, Y.; Zhang, C.Q.; Wang, Y.; Wang, S.; Chen, W.-F. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma FREE British J. Cancer, 2005, 92, 929-934.